Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.
|Articles|January 1, 2006
Adopting free EMRs without violating STARK laws
The Centers for Medicare & Medicaid Services (CMS) and the Office of the Inspector General (OIG) have proposed new rules that would relax regulations that prevent physicians who care for Medicare patients from getting free electronic medical record (EMR) technology from a health-care partner. Currently, if physicians accept such a gift, they risk violating federal Stark laws and anti-kickback statutes. To avoid the appearance of an improper financial relationship, physicians can pay fair market price for information technology products. This, however, is a major barrier to adopting an interoperable electronic health-care system—especially among individual physicians and small practices, according to American Medical News (10/24-31/05).
Advertisement
Advertisement
Related to this article
Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
Susan Reed, MD, MPH, MS, and Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, weigh in on FDA boxed warning removals for menopausal hormone therapy.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
A recap of the top women's health headlines from October 2026, including FDA approval of pritelivir for refractory HSV, ACOG's new menopause guideline, and more.
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA removes boxed warnings from 3 more menopausal hormone therapy products
2
Choosing Among Hormonal and Nonhormonal VMS Therapies in Menopause
3
Top headlines in women's health from October 2026
4
FDA grants accelerated approval to DNA immunotherapy for adult recurrent respiratory papillomatosis
5